Weekly dose Units per injection (mL) Syringe fill level Once the deficiency is fixed, a monthly maintenance protocol of 1,000 mcg injections is suggested
By checking your skin daily, keeping a skin diary, and taking photos of any changes, you can monitor for recurring skin reactions effectively
SURPASS-4 is the largest and longest trial in the SURPASS project so far, and it is also the fifth and last completed global registration study on tirzepatide for the treatment of type 2 diabetes
However, a well-designed astaxanthin supplement can offer more than astaxanthin alone
For instance, Novo Nordisks semaglutide-based drugs (Ozempic, Wegovy) face competition from Eli Lillys tirzepatide-based Mounjaro and Zepbound, which have demonstrated superior weight loss efficacy, while Novo Nordisks CagriSema has recently shown promising but not market-leading results, further intensifying industry competition
A new pathway to access Wegovy for obesity The Medicare GLP-1 Bridge Program is a nationwide, short-term CMS program designed to cover select weight-management drugs for Medicare Part D beneficiaries Medicare GLP-1 Bridge Program Eligible patients can access all doses of Wegovy pill and pen for only Starting July 1, 2026 1 Medicare GLP-1 Bridge Program eligibility 1 Medication prescribed for weight management, in combination with current and ongoing lifestyle modification consistent with the applicable FDA-approved label Enrolled in a Medicare Part D plan (stand-alone PDP or MA PD), including Special Needs Plans (SNPs), employer/union group waiver plans (EGWPs), Limited Income Newly Eligible Transition (LI NET), and dual-eligible beneficiaries who are enrolled in eligible Part D plan types 18 years of age BMI 35 kg/m 2 or BMI 30 kg/m 2 + 1 or more of the following comorbidities Uncontrolled HTN, HFpEF, CKD Stage 3a, or above or BMI 27 kg/m 2 + 1 or more comorbidities Pre-diabetes, previous stroke/MI, symptomatic PAD Terms apply
